BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33649794)

  • 1. Bcl2l10 induces metabolic alterations in ovarian cancer cells by regulating the TCA cycle enzymes SDHD and IDH1.
    Lee SY; Kwon J; Lee KA
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl2l10 mediates the proliferation, invasion and migration of ovarian cancer cells.
    Lee SY; Kwon J; Woo JH; Kim KH; Lee KA
    Int J Oncol; 2020 Feb; 56(2):618-629. PubMed ID: 31894274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Succinate dehydrogenase subunit B inhibits the AMPK-HIF-1α pathway in human ovarian cancer in vitro.
    Chen L; Liu T; Zhang S; Zhou J; Wang Y; Di W
    J Ovarian Res; 2014 Dec; 7():115. PubMed ID: 25491408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL2L10 inhibits growth and metastasis of hepatocellular carcinoma both in vitro and in vivo.
    Bai Y; Wang J; Han J; Xie XL; Ji CG; Yin J; Chen L; Wang CK; Jiang XY; Qi W; Jiang HQ
    Mol Carcinog; 2017 Mar; 56(3):1137-1149. PubMed ID: 27770580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL2L10 protein regulates apoptosis/proliferation through differential pathways in gastric cancer cells.
    Xu JD; Cao XX; Long ZW; Liu XP; Furuya T; Xu JW; Liu XL; De Xu Z; Sasaki K; Li QQ
    J Pathol; 2011 Feb; 223(3):400-9. PubMed ID: 21171085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting the TCA cycle: signaling to tumor formation.
    Raimundo N; Baysal BE; Shadel GS
    Trends Mol Med; 2011 Nov; 17(11):641-9. PubMed ID: 21764377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNOT7 modulates biological functions of ovarian cancer cells via AKT signaling pathway.
    Yu J; Hu X; Chen X; Zhou Q; Jiang Q; Shi Z; Zhu H
    Life Sci; 2021 Mar; 268():118996. PubMed ID: 33412213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of succinate dehydrogenase sensitizes cyclin E-driven ovarian cancer to CDK inhibition.
    Guo T; Gu C; Chen X; Kang Y; Li B; Xu C
    Biofactors; 2016; 42(2):171-8. PubMed ID: 26826064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.
    Khurshed M; Molenaar RJ; Lenting K; Leenders WP; van Noorden CJF
    Oncotarget; 2017 Jul; 8(30):49165-49177. PubMed ID: 28467784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer?
    Laurenti G; Tennant DA
    Biochem Soc Trans; 2016 Aug; 44(4):1111-6. PubMed ID: 27528759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-148a inhibits migration and invasion of ovarian cancer cells via targeting sphingosine-1-phosphate receptor 1.
    Wen Z; Zhao S; Liu S; Liu Y; Li X; Li S
    Mol Med Rep; 2015 Sep; 12(3):3775-3780. PubMed ID: 26004261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C; Wang M; Shi C; Shi F; Pei C
    Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inborn and acquired metabolic defects in cancer.
    Frezza C; Pollard PJ; Gottlieb E
    J Mol Med (Berl); 2011 Mar; 89(3):213-20. PubMed ID: 21301796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
    Shen X; Wu S; Zhang J; Li M; Xu F; Wang A; Lei Y; Zhu G
    Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type IDH1 Knockout Leads to G0/G1 Arrest, Impairs Cancer Cell Proliferation, Altering Glycolysis, and the TCA Cycle in Colon Cancer.
    Atalay EB; Senturk S; Kayali HA
    Biochem Genet; 2023 Aug; 61(4):1470-1486. PubMed ID: 36633771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive circular RNA expression profiles and the tumor-suppressive function of circHIPK3 in ovarian cancer.
    Teng F; Xu J; Zhang M; Liu S; Gu Y; Zhang M; Wang X; Ni J; Qian B; Shen R; Jia X
    Int J Biochem Cell Biol; 2019 Jul; 112():8-17. PubMed ID: 31026505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
    Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
    J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF-κB controls four genes encoding core enzymes of tricarboxylic acid cycle.
    Zhou F; Xu X; Wu J; Wang D; Wang J
    Gene; 2017 Jul; 621():12-20. PubMed ID: 28400269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
    Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
    Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.